Metaclipse Therapeutics-preview

Metaclipse

Metaclipse Therapeutics

Private

Atlanta, GeorgiaHealthcare & Life Scienceshttps://metaclipse.com/

Last Round

Grant

Sep 1, 2025

Total Funding Raised

$16.26M

Momentum Score

50 /100

Company Overview

Metaclipse Therapeutics is a biotechnology company that develops next-generation immunotherapies to treat cancer and vaccines to prevent infectious diseases using its proprietary biological adjuvants.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2G

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

cancer immunotherapyimmuno-oncologypersonalized cancer vaccineautologous immunotherapycancer vaccineclinical-stage biotechinfectious disease vaccinesolid tumorsbiological adjuvantspharmaceutical licensingVLP vaccineextracellular vesicle therapytriple-negative breast cancerTNBChead and neck cancerHNSCC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Metaclipse Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Metaclipse Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Sep 1, 2025
Grant	Nov 20, 2024
Grant	May 1, 2023
Grant	Sep 1, 2021
Series A	Nov 1, 2020
Grant	Jun 1, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Shaker J. C. Reddy

PRESIDENT CEO CO FOUNDER

Founding Team

Metaclipse Therapeutics Investors

Notable investors and investment history

Investor	Rounds
National Cancer Institute	Grant
National Institute of Allergy and Infectious Diseases	Grant
NIH RADx	Grant
Georgia Research Alliance	Seed
Cancer Prevention and Research Institute of Texas	Grant

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 15, 2026
Monthly visitors increased 75% MoM.
Feb 19, 2026
Grew 50% QoQ from 6 to 9 employees.

View all signals

Metaclipse Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Metaclipse Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Metaclipse Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersAtlanta, Georgia

Employee Range9

Year Founded2012

Last FundingSep 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.